Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1073339-13-5

Post Buying Request

1073339-13-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 4-Chloro-2-fluoro-5-(methoxycarbonyl)phenylboronic acid, pinacol ester

    Cas No: 1073339-13-5

  • No Data

  • No Data

  • No Data

  • BOC Sciences
  • Contact Supplier

1073339-13-5 Usage

Uses

4-Chloro-2-fluoro-5-(methoxycarbonyl)phenylboronic acid, pinacol ester

Check Digit Verification of cas no

The CAS Registry Mumber 1073339-13-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,3,3,3 and 9 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1073339-13:
(9*1)+(8*0)+(7*7)+(6*3)+(5*3)+(4*3)+(3*9)+(2*1)+(1*3)=135
135 % 10 = 5
So 1073339-13-5 is a valid CAS Registry Number.

1073339-13-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name Methyl 2-chloro-4-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

1.2 Other means of identification

Product number -
Other names methyl 2-chloro-4-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1073339-13-5 SDS

1073339-13-5Downstream Products

1073339-13-5Relevant articles and documents

Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors

Bagal, Sharan K.,Omoto, Kiyoyuki,Blakemore, David C.,Bungay, Peter J.,Bilsland, James G.,Clarke, Philip J.,Corbett, Matthew S.,Cronin, Ciaran N.,Cui, J. Jean,Dias, Rebecca,Flanagan, Neil J.,Greasley, Samantha E.,Grimley, Rachel,Johnson, Eric,Fengas, David,Kitching, Linda,Kraus, Michelle L.,McAlpine, Indrawan,Nagata, Asako,Waldron, Gareth J.,Warmus, Joseph S.

, p. 247 - 265 (2018)

Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound 23.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1073339-13-5